The Perelman School of Medicine at the University of Pennsylvania and ViralEd are proud to announce the extension of this ground-breaking CME activity. Mirroring academic grand rounds programs, these CME-certified sessions combine traditional academic grand rounds with the innovation and convenience of telemedicine. The "HIV Grand Rounds from the Perelman School of Medicine at the University of Pennsylvania" is delivered live via the Internet every Thursday at noon (12 PM) Eastern Time and is available for on-demand viewing twenty-four hours after the live broadcast.
Presentations cover the most important and current topics in HIV/AIDS and are delivered by the top experts in the field. They are designed to be immediately relevant to practicing HIV clinicians and many are case-based. The final 10 minutes of each one-hour educational activity consists of a live question and answer period, with the presenting faculty member available to answer questions asked by attendees using the webinar interface. These weekly grand rounds are intended to provide clinicians with convenient and easily accessible knowledge and clinical skills they need to provide the best medical care for their HIV-positive patients.
Each session may be broadcast via your Internet connection in your conference room or auditorium for large groups to view, or individually to your personal computer at your convenience. Simply register at www.viraled.com/grandrounds for easy access.
This educational activity is designed for HIV specialists, Infectious Disease specialists, Internal Medicine specialists, Family Practice physicians, Dermatologists, Osteo-specialists, Nephrologists, Hematology/oncologist, Psychiatrists, Public Health professionals, OB/GYN physicians and other clinicians interested and involved in the care of patients with HIV/AIDS.
These activities are supported by educational grants from Gilead Sciences and Janssen Therapeutics.
Upon completion of the educational activity, participants should be able to:
|John Bartlett, MD
Professor of Medicine,
Johns Hopkins School of Medicine
|Calvin J. Cohen, MD, MS
CRI New England
Harvard Medical School
|Ian Frank, MD
Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Helen Koenig MD MPH
|Amy Pruitt MD
Associate Professor fo Neurology
Division Shief, General Neurology
Hospital of the University of Pennsylvania
|David Holtzman MD
University of Pennsylvania
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and ViralEd, LLC. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.
The Perelman School of Medicine at the University of Pennsylvania designates each live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is policy at the Perelman School of Medicine at the University of Pennsylvania and ViralEd, LLC for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania (Rodman Campbell, Mila Kostic, Belinda Rose, and Mindy Pollock Troy), our educational partner ViralEd, LLC (Richard Gordon, Brian Boyle, MD, JD and Ed Hettman), and the peer reviewer, Zalman Agus, MD, Associate Dean for Continuing Medical Education, have reported that they have no relevant financial relationships with any commercial interests related to the content of this educational activity.
The following faculty or planning committee members have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity:
|John Bartlett, MD|
The following faculty or planning committee members have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity:
|Calvin Cohen, MD||Gilead; Bristol-Myers Squibb; Merck & Co.||Contracted Research|
|Gilead; Bristol-Myers Squibb; Merck & Co.; Tobira||Honoraria|
|Ian Frank, MD||GlaxoSmithKline, Merck & Co.||Contracted Research|
|Gilead, Tibotec||Consulting Fees|
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ViralEd, LLC, the Perelman School of Medicine at the University of Pennsylvania, Gilead Sciences and Janssen Therapeutics do not recommend the use of any agent outside of the labeled indications.
|Presenter||Product||Invetigational and/or Off-label Use|
|Amy Pruitt MD||Mefloquine & Codofovir||Progressive Multifocal Leukoencephalopathy|
|Cotricosteroids||Immune Reonstitution Inflammatory Syndrome / Progressive Multifocal Leukoencephalopathy|
|Helen Koenig MD MPH||Mirtazapine; Mefloquine; Cytarabine; Cidofovir||Progressive Multifocal Leukoencephalopathy|
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of ViralEd, LLC, the Perelman School of Medicine at the University of Pennsylvania, Gilead Sciences and Janssen Therapeutics. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.